-
1
-
-
77955635233
-
Cancer statistics, 2010
-
10.3322/caac.20073, 20610543
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
-
(2010)
CA Cancer J Clin
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
37549020086
-
Clinical practice. localized prostate cancer
-
18160689
-
Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. localized prostate cancer. N Engl J Med 2007, 357(26):2696-2705. 10.1056/NEJMcp0706784, 18160689.
-
(2007)
N Engl J Med
, vol.357
, Issue.26
, pp. 2696-2705
-
-
Walsh, P.C.1
DeWeese, T.L.2
Eisenberger, M.A.3
-
3
-
-
33749345244
-
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
-
2360544, 16983403
-
Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006, 95(7):767-774. 10.1038/sj.bjc.6603223, 2360544, 16983403.
-
(2006)
Br J Cancer
, vol.95
, Issue.7
, pp. 767-774
-
-
Attard, G.1
Sarker, D.2
Reid, A.3
Molife, R.4
Parker, C.5
de Bono, J.S.6
-
4
-
-
79959249179
-
Characterization of bone metastases from rapid autopsies of prostate cancer patients
-
3117947, 21555375
-
Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011, 17(12):3924-3932. 10.1158/1078-0432.CCR-10-3120, 3117947, 21555375.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.12
, pp. 3924-3932
-
-
Mehra, R.1
Kumar-Sinha, C.2
Shankar, S.3
Lonigro, R.J.4
Jing, X.5
Philips, N.E.6
Siddiqui, J.7
Han, B.8
Cao, X.9
Smith, D.C.10
Shah, R.B.11
Chinnaiyan, A.M.12
Pienta, K.J.13
-
5
-
-
84864569535
-
Novel options for the treatment of castration-resistant prostate cancer
-
22101903
-
Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ. Novel options for the treatment of castration-resistant prostate cancer. World J Urol 2012, 30(4):495-503. 10.1007/s00345-011-0796-7, 22101903.
-
(2012)
World J Urol
, vol.30
, Issue.4
, pp. 495-503
-
-
Ohlmann, C.H.1
Merseburger, A.S.2
Suttmann, H.3
Schilling, D.4
Trojan, L.5
Kempkensteffen, C.6
Corvin, S.7
Mathers, M.J.8
Bastian, P.J.9
-
6
-
-
78650305379
-
Treatment and prevention of bone complications from prostate cancer
-
3010497, 20621630
-
Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone 2011, 48(1):88-95. 10.1016/j.bone.2010.05.038, 3010497, 20621630.
-
(2011)
Bone
, vol.48
, Issue.1
, pp. 88-95
-
-
Lee, R.J.1
Saylor, P.J.2
Smith, M.R.3
-
7
-
-
79958037582
-
Bone metastasis in prostate cancer: emerging therapeutic strategies
-
Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8(6):357-368.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.6
, pp. 357-368
-
-
Sturge, J.1
Caley, M.P.2
Waxman, J.3
-
8
-
-
83255186301
-
Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)
-
22146228
-
Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc) 2011, 47(11):857-868. 10.1358/dot.2011.47.11.1688487, 22146228.
-
(2011)
Drugs Today (Barc)
, vol.47
, Issue.11
, pp. 857-868
-
-
Bowles, D.W.1
Kessler, E.R.2
Jimeno, A.3
-
9
-
-
83355166909
-
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
-
21926191
-
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011, 10(12):2298-2308. 10.1158/1535-7163.MCT-11-0264, 21926191.
-
(2011)
Mol Cancer Ther
, vol.10
, Issue.12
, pp. 2298-2308
-
-
Yakes, F.M.1
Chen, J.2
Tan, J.3
Yamaguchi, K.4
Shi, Y.5
Yu, P.6
Qian, F.7
Chu, F.8
Bentzien, F.9
Cancilla, B.10
Orf, J.11
You, A.12
Laird, A.D.13
Engst, S.14
Lee, L.15
Lesch, J.16
Chou, Y.C.17
Joly, A.H.18
-
10
-
-
0032818964
-
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
-
10475365
-
Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54(3):523-527. 10.1016/S0090-4295(99)00167-3, 10475365.
-
(1999)
Urology
, vol.54
, Issue.3
, pp. 523-527
-
-
Duque, J.L.1
Loughlin, K.R.2
Adam, R.M.3
Kantoff, P.W.4
Zurakowski, D.5
Freeman, M.R.6
-
11
-
-
0027717345
-
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
-
1887042, 7688183
-
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409. 1887042, 7688183.
-
(1993)
Am J Pathol
, vol.143
, Issue.2
, pp. 401-409
-
-
Weidner, N.1
Carroll, P.R.2
Flax, J.3
Blumenfeld, W.4
Folkman, J.5
-
12
-
-
80051552737
-
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer
-
21600762
-
Merino M, Pinto A, Gonzalez R, Espinosa E. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer 2011, 47(12):1846-1851. 10.1016/j.ejca.2011.04.020, 21600762.
-
(2011)
Eur J Cancer
, vol.47
, Issue.12
, pp. 1846-1851
-
-
Merino, M.1
Pinto, A.2
Gonzalez, R.3
Espinosa, E.4
-
13
-
-
0036192486
-
Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts
-
11882460
-
Mayr-Wohlfart U, Waltenberger J, Hausser H, Kessler S, Gunther KP, Dehio C, Puhl W, Brenner RE. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002, 30(3):472-477. 10.1016/S8756-3282(01)00690-1, 11882460.
-
(2002)
Bone
, vol.30
, Issue.3
, pp. 472-477
-
-
Mayr-Wohlfart, U.1
Waltenberger, J.2
Hausser, H.3
Kessler, S.4
Gunther, K.P.5
Dehio, C.6
Puhl, W.7
Brenner, R.E.8
-
14
-
-
0028237788
-
Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts
-
8123039
-
Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994, 199(1):380-386. 10.1006/bbrc.1994.1240, 8123039.
-
(1994)
Biochem Biophys Res Commun
, vol.199
, Issue.1
, pp. 380-386
-
-
Midy, V.1
Plouet, J.2
-
15
-
-
10744225879
-
Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein
-
14871830
-
Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004, 64(3):994-999. 10.1158/0008-5472.CAN-03-1382, 14871830.
-
(2004)
Cancer Res
, vol.64
, Issue.3
, pp. 994-999
-
-
Dai, J.1
Kitagawa, Y.2
Zhang, J.3
Yao, Z.4
Mizokami, A.5
Cheng, S.6
Nor, J.7
McCauley, L.K.8
Taichman, R.S.9
Keller, E.T.10
-
16
-
-
28244481510
-
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity
-
16322239
-
Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005, 65(23):10921-10929. 10.1158/0008-5472.CAN-05-1809, 16322239.
-
(2005)
Cancer Res
, vol.65
, Issue.23
, pp. 10921-10929
-
-
Kitagawa, Y.1
Dai, J.2
Zhang, J.3
Keller, J.M.4
Nor, J.5
Yao, Z.6
Keller, E.T.7
-
17
-
-
0036570938
-
Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion
-
11948964
-
van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002, 51(2):98-107. 10.1002/pros.10073, 11948964.
-
(2002)
Prostate
, vol.51
, Issue.2
, pp. 98-107
-
-
van Leenders, G.1
van Balken, B.2
Aalders, T.3
Hulsbergen-van de Kaa, C.4
Ruiter, D.5
Schalken, J.6
-
18
-
-
0029082188
-
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma
-
1869824, 7639332
-
Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147(2):386-396. 1869824, 7639332.
-
(1995)
Am J Pathol
, vol.147
, Issue.2
, pp. 386-396
-
-
Humphrey, P.A.1
Zhu, X.2
Zarnegar, R.3
Swanson, P.E.4
Ratliff, T.L.5
Vollmer, R.T.6
Day, M.L.7
-
19
-
-
0036899998
-
High expression of the Met receptor in prostate cancer metastasis to bone
-
12475693
-
Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002, 60(6):1113-1117. 10.1016/S0090-4295(02)01954-4, 12475693.
-
(2002)
Urology
, vol.60
, Issue.6
, pp. 1113-1117
-
-
Knudsen, B.S.1
Gmyrek, G.A.2
Inra, J.3
Scherr, D.S.4
Vaughan, E.D.5
Nanus, D.M.6
Kattan, M.W.7
Gerald, W.L.8
Vande Woude, G.F.9
-
20
-
-
84860330623
-
Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases
-
21882211
-
Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P, Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2012, 72(7):713-720. 10.1002/pros.21473, 21882211.
-
(2012)
Prostate
, vol.72
, Issue.7
, pp. 713-720
-
-
Colombel, M.1
Eaton, C.L.2
Hamdy, F.3
Ricci, E.4
van der Pluijm, G.5
Cecchini, M.6
Mege-Lechevallier, F.7
Clezardin, P.8
Thalmann, G.9
-
21
-
-
67650360799
-
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer
-
19549766
-
Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009, 15(13):4292-4298. 10.1158/1078-0432.CCR-09-0599, 19549766.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.13
, pp. 4292-4298
-
-
Russo, A.L.1
Jedlicka, K.2
Wernick, M.3
McNally, D.4
Kirk, M.5
Sproull, M.6
Smith, S.7
Shankavaram, U.8
Kaushal, A.9
Figg, W.D.10
Dahut, W.11
Citrin, D.12
Bottaro, D.P.13
Albert, P.S.14
Tofilon, P.J.15
Camphausen, K.16
-
22
-
-
33847057016
-
The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression
-
17283128
-
Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67(3):967-975. 10.1158/0008-5472.CAN-06-3552, 17283128.
-
(2007)
Cancer Res
, vol.67
, Issue.3
, pp. 967-975
-
-
Verras, M.1
Lee, J.2
Xue, H.3
Li, T.H.4
Wang, Y.5
Sun, Z.6
-
23
-
-
58149337448
-
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
-
19010843
-
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14(22):7272-7283. 10.1158/1078-0432.CCR-08-0652, 19010843.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.22
, pp. 7272-7283
-
-
Hu-Lowe, D.D.1
Zou, H.Y.2
Grazzini, M.L.3
Hallin, M.E.4
Wickman, G.R.5
Amundson, K.6
Chen, J.H.7
Rewolinski, D.A.8
Yamazaki, S.9
Wu, E.Y.10
McTigue, M.A.11
Murray, B.W.12
Kania, R.S.13
O'Connor, P.14
Shalinsky, D.R.15
Bender, S.L.16
-
24
-
-
80052806086
-
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
-
21812414
-
Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011, 54(18):6342-6363. 10.1021/jm2007613, 21812414.
-
(2011)
J Med Chem
, vol.54
, Issue.18
, pp. 6342-6363
-
-
Cui, J.J.1
Tran-Dube, M.2
Shen, H.3
Nambu, M.4
Kung, P.P.5
Pairish, M.6
Jia, L.7
Meng, J.8
Funk, L.9
Botrous, I.10
McTigue, M.11
Grodsky, N.12
Ryan, K.13
Padrique, E.14
Alton, G.15
Timofeevski, S.16
Yamazaki, S.17
Li, Q.18
Zou, H.19
Christensen, J.20
Mroczkowski, B.21
Bender, S.22
Kania, R.S.23
Edwards, M.P.24
more..
-
25
-
-
60549088318
-
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone
-
2698812, 19176388
-
Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009, 69(4):1685-1692. 10.1158/0008-5472.CAN-08-2164, 2698812, 19176388.
-
(2009)
Cancer Res
, vol.69
, Issue.4
, pp. 1685-1692
-
-
Li, X.1
Loberg, R.2
Liao, J.3
Ying, C.4
Snyder, L.A.5
Pienta, K.J.6
McCauley, L.K.7
-
26
-
-
79953272413
-
Pre-clinical mouse models of human prostate cancer and their utility in drug discovery
-
3072580, 21483646, Chapter 14, Unit 14 15
-
Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2010, Chapter 14:Unit 14 15. 3072580, 21483646.
-
(2010)
Curr Protoc Pharmacol
-
-
Park, S.I.1
Kim, S.J.2
McCauley, L.K.3
Gallick, G.E.4
-
27
-
-
0036604237
-
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells
-
11992617
-
Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002, 52(1):20-33. 10.1002/pros.10091, 11992617.
-
(2002)
Prostate
, vol.52
, Issue.1
, pp. 20-33
-
-
Corey, E.1
Quinn, J.E.2
Bladou, F.3
Brown, L.G.4
Roudier, M.P.5
Brown, J.M.6
Buhler, K.R.7
Vessella, R.L.8
-
28
-
-
84872967522
-
Cancer statistics, 2013
-
10.3322/caac.21166, 23335087
-
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
-
(2013)
CA Cancer J Clin
, vol.63
, Issue.1
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
29
-
-
69249203584
-
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets
-
19560857
-
Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder FH, Sternberg C, Tombal B, Visakorpi T. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009, 56(4):594-605. 10.1016/j.eururo.2009.06.027, 19560857.
-
(2009)
Eur Urol
, vol.56
, Issue.4
, pp. 594-605
-
-
Chi, K.N.1
Bjartell, A.2
Dearnaley, D.3
Saad, F.4
Schroder, F.H.5
Sternberg, C.6
Tombal, B.7
Visakorpi, T.8
-
30
-
-
41949104346
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
-
4010133, 18309951, Prostate Cancer Clinical Trials Working G
-
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26(7):1148-1159. 10.1200/JCO.2007.12.4487, 4010133, 18309951, Prostate Cancer Clinical Trials Working G.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
Morris, M.4
Sternberg, C.N.5
Carducci, M.A.6
Eisenberger, M.A.7
Higano, C.8
Bubley, G.J.9
Dreicer, R.10
Petrylak, D.11
Kantoff, P.12
Basch, E.13
Kelly, W.K.14
Figg, W.D.15
Small, E.J.16
Beer, T.M.17
Wilding, G.18
Martin, A.19
Hussain, M.20
more..
-
31
-
-
66149161780
-
Castration-resistant prostate cancer: locking up the molecular escape routes
-
19447877
-
Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009, 15(10):3251-3255. 10.1158/1078-0432.CCR-08-1171, 19447877.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.10
, pp. 3251-3255
-
-
Attar, R.M.1
Takimoto, C.H.2
Gottardis, M.M.3
-
32
-
-
33644675811
-
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
-
16278481
-
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23(32):8253-8261. 10.1200/JCO.2005.03.4777, 16278481.
-
(2005)
J Clin Oncol
, vol.23
, Issue.32
, pp. 8253-8261
-
-
Scher, H.I.1
Sawyers, C.L.2
-
33
-
-
0035010803
-
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
-
11417967
-
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176. 10.1053/ctrv.2000.0210, 11417967.
-
(2001)
Cancer Treat Rev
, vol.27
, Issue.3
, pp. 165-176
-
-
Coleman, R.E.1
-
34
-
-
77949347731
-
Pathogenesis of osteoblastic bone metastases from prostate cancer
-
20108337
-
Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116(6):1406-1418. 10.1002/cncr.24896, 20108337.
-
(2010)
Cancer
, vol.116
, Issue.6
, pp. 1406-1418
-
-
Ibrahim, T.1
Flamini, E.2
Mercatali, L.3
Sacanna, E.4
Serra, P.5
Amadori, D.6
-
35
-
-
0041670903
-
Skeletal implications of prostate cancer
-
Bagi CM. Skeletal implications of prostate cancer. J Musculoskelet Neuronal Interact 2003, 3(2):112-117.
-
(2003)
J Musculoskelet Neuronal Interact
, vol.3
, Issue.2
, pp. 112-117
-
-
Bagi, C.M.1
-
36
-
-
11344267803
-
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
-
14991763
-
Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91(4):718-729. 10.1002/jcb.10662, 14991763.
-
(2004)
J Cell Biochem
, vol.91
, Issue.4
, pp. 718-729
-
-
Keller, E.T.1
Brown, J.2
-
37
-
-
11144237716
-
Osteoblasts in prostate cancer metastasis to bone
-
15630412
-
Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5(1):21-28. 10.1038/nrc1528, 15630412.
-
(2005)
Nat Rev Cancer
, vol.5
, Issue.1
, pp. 21-28
-
-
Logothetis, C.J.1
Lin, S.H.2
-
38
-
-
34548584066
-
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
-
17262196
-
DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15(7):869-876. 10.1007/s00520-006-0203-x, 17262196.
-
(2007)
Support Care Cancer
, vol.15
, Issue.7
, pp. 869-876
-
-
DePuy, V.1
Anstrom, K.J.2
Castel, L.D.3
Schulman, K.A.4
Weinfurt, K.P.5
Saad, F.6
-
39
-
-
43949146650
-
The cost of treating skeletal-related events in patients with prostate cancer
-
Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14(5):317-322.
-
(2008)
Am J Manag Care
, vol.14
, Issue.5
, pp. 317-322
-
-
Lage, M.J.1
Barber, B.L.2
Harrison, D.J.3
Jun, S.4
-
40
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
15173273, Zoledronic Acid Prostate Cancer Study G
-
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study G Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96(11):879-882. 10.1093/jnci/djh141, 15173273, Zoledronic Acid Prostate Cancer Study G.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.11
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
Tchekmedyian, S.4
Venner, P.5
Lacombe, L.6
Chin, J.L.7
Vinholes, J.J.8
Goas, J.A.9
Zheng, M.10
-
41
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
-
3090685, 21353695
-
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822. 10.1016/S0140-6736(10)62344-6, 3090685, 21353695.
-
(2011)
Lancet
, vol.377
, Issue.9768
, pp. 813-822
-
-
Fizazi, K.1
Carducci, M.2
Smith, M.3
Damiao, R.4
Brown, J.5
Karsh, L.6
Milecki, P.7
Shore, N.8
Rader, M.9
Wang, H.10
Jiang, Q.11
Tadros, S.12
Dansey, R.13
Goessl, C.14
-
42
-
-
84874787799
-
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
-
4110249, 23169517
-
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013, 31(4):412-419. 10.1200/JCO.2012.45.0494, 4110249, 23169517.
-
(2013)
J Clin Oncol
, vol.31
, Issue.4
, pp. 412-419
-
-
Smith, D.C.1
Smith, M.R.2
Sweeney, C.3
Elfiky, A.A.4
Logothetis, C.5
Corn, P.G.6
Vogelzang, N.J.7
Small, E.J.8
Harzstark, A.L.9
Gordon, M.S.10
Vaishampayan, U.N.11
Haas, N.B.12
Spira, A.I.13
Lara, P.N.14
Lin, C.C.15
Srinivas, S.16
Sella, A.17
Schoffski, P.18
Scheffold, C.19
Weitzman, A.L.20
Hussain, M.21
more..
-
43
-
-
0345601083
-
Met, metastasis, motility and more
-
14685170
-
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4(12):915-925. 10.1038/nrm1261, 14685170.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, Issue.12
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande Woude, G.F.4
-
44
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
17483355
-
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67(9):4408-4417. 10.1158/0008-5472.CAN-06-4443, 17483355.
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
Arango, M.E.4
McDonnell, S.R.5
Yamazaki, S.6
Koudriakova, T.B.7
Alton, G.8
Cui, J.J.9
Kung, P.P.10
Nambu, M.D.11
Los, G.12
Bender, S.L.13
Mroczkowski, B.14
Christensen, J.G.15
-
45
-
-
79960738374
-
Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer
-
3146625, 21365123
-
Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 2011, 17(7-8):657-664. 3146625, 21365123.
-
(2011)
Mol Med
, vol.17
, Issue.7-8
, pp. 657-664
-
-
Pfeiffer, M.J.1
Smit, F.P.2
Sedelaar, J.P.3
Schalken, J.A.4
-
46
-
-
0029797701
-
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro
-
38800, 8755529
-
Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996, 93(15):7644-7648. 10.1073/pnas.93.15.7644, 38800, 8755529.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, Issue.15
, pp. 7644-7648
-
-
Grano, M.1
Galimi, F.2
Zambonin, G.3
Colucci, S.4
Cottone, E.5
Zallone, A.Z.6
Comoglio, P.M.7
-
47
-
-
0029001626
-
Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6)
-
7790391
-
Sato T, Hakeda Y, Yamaguchi Y, Mano H, Tezuka K, Matsumoto K, Nakamura T, Mori Y, Yoshizawa K, Sumitani K. Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995, 164(1):197-204. 10.1002/jcp.1041640124, 7790391.
-
(1995)
J Cell Physiol
, vol.164
, Issue.1
, pp. 197-204
-
-
Sato, T.1
Hakeda, Y.2
Yamaguchi, Y.3
Mano, H.4
Tezuka, K.5
Matsumoto, K.6
Nakamura, T.7
Mori, Y.8
Yoshizawa, K.9
Sumitani, K.10
-
48
-
-
0034772250
-
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
-
Cancer, Leukemia Group B
-
George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW, Cancer, Leukemia Group B Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001, 7(7):1932-1936. Cancer, Leukemia Group B.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.7
, pp. 1932-1936
-
-
George, D.J.1
Halabi, S.2
Shepard, T.F.3
Vogelzang, N.J.4
Hayes, D.F.5
Small, E.J.6
Kantoff, P.W.7
-
49
-
-
67651112022
-
Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism
-
2701940, 19527527
-
Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res 2009, 4:19. 10.1186/1749-799X-4-19, 2701940, 19527527.
-
(2009)
J Orthop Surg Res
, vol.4
, pp. 19
-
-
Street, J.1
Lenehan, B.2
|